Log in

OraSure Technologies Stock Forecast, Price & News

-0.19 (-1.57 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $11.89
50-Day Range
MA: $13.42
52-Week Range
Now: $11.89
Volume796,547 shs
Average Volume1.55 million shs
Market Capitalization$852.91 million
P/E RatioN/A
Dividend YieldN/A
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, and OraSure QuickFlu Rapid Flu A&B test; OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; tuberculosis products; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.
OraSure Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:OSUR



Sales & Book Value

Annual Sales$154.60 million
Cash Flow$0.18 per share
Book Value$4.98 per share


Net Income$16.66 million


Market Cap$852.91 million
Next Earnings Date2/17/2021 (Estimated)
-0.19 (-1.57 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OSUR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions

How has OraSure Technologies' stock price been impacted by COVID-19?

OraSure Technologies' stock was trading at $5.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OSUR shares have increased by 101.5% and is now trading at $11.89.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of OraSure Technologies?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for OraSure Technologies
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than OraSure Technologies?

Wall Street analysts have given OraSure Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OraSure Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OraSure Technologies' next earnings date?

OraSure Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, February 17th 2021.
View our earnings forecast for OraSure Technologies

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) posted its earnings results on Wednesday, November, 4th. The medical instruments supplier reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.07. The medical instruments supplier earned $48.01 million during the quarter, compared to the consensus estimate of $39.20 million. OraSure Technologies had a negative net margin of 1.57% and a negative return on equity of 3.08%. The business's quarterly revenue was up 33.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.21 earnings per share.
View OraSure Technologies' earnings history

What guidance has OraSure Technologies issued on next quarter's earnings?

OraSure Technologies issued an update on its fourth quarter 2020 After-Hours earnings guidance on Wednesday, November, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $55-60 million, compared to the consensus revenue estimate of $61.46 million.

What price target have analysts set for OSUR?

6 analysts have issued 12 month target prices for OraSure Technologies' shares. Their forecasts range from $14.00 to $22.00. On average, they anticipate OraSure Technologies' share price to reach $17.83 in the next twelve months. This suggests a possible upside of 50.0% from the stock's current price.
View analysts' price targets for OraSure Technologies

Who are some of OraSure Technologies' key competitors?

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), Energy Transfer (ET), XOMA (XOMA), Overstock.com (OSTK), Ford Motor (F), Pfizer (PFE), Abbott Laboratories (ABT), Advanced Micro Devices (AMD) and Activision Blizzard (ATVI).

Who are OraSure Technologies' key executives?

OraSure Technologies' management team includes the following people:
  • Dr. Stephen S. Tang, Pres, CEO & Director (Age 59, Pay $871.83k)
  • Mr. Roberto E. Cuca, CFO & Principal Accounting Officer (Age 52, Pay $562.6k)
  • Mr. Jack E. Jerrett, Sr. VP, Chief Compliance Officer, Gen. Counsel & Sec. (Age 61, Pay $477.29k)
  • Ms. Kathleen Gallagher Weber, Exec. VP & Bus. Unit Leader of Molecular Solutions (Age 53, Pay $530.29k)
  • Ms. Jeanne Mell, VP of Corp. Communications
  • Ms. Lisa Nibauer, Exec. VP & Bus. Unit Leader of Infectious Disease
  • Ms. Michele Marie Miller, VP of Fin., Controller & Assistant Sec. (Age 46)

What is OraSure Technologies' stock symbol?

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.13%), State Street Corp (4.31%), Camber Capital Management LP (3.83%), Point72 Asset Management L.P. (2.24%), Neuberger Berman Group LLC (1.91%) and Archon Capital Management LLC (1.40%). Company insiders that own OraSure Technologies stock include Jack E Jerrett, Roberto Cuca and Stephen S Phd Tang.
View institutional ownership trends for OraSure Technologies

Which institutional investors are selling OraSure Technologies stock?

OSUR stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, JPMorgan Chase & Co., SG Americas Securities LLC, Squarepoint Ops LLC, Fisher Asset Management LLC, Cubist Systematic Strategies LLC, Principal Financial Group Inc., and Nisa Investment Advisors LLC.
View insider buying and selling activity for OraSure Technologies

Which institutional investors are buying OraSure Technologies stock?

OSUR stock was acquired by a variety of institutional investors in the last quarter, including Camber Capital Management LP, BlackRock Inc., Kornitzer Capital Management Inc. KS, Tygh Capital Management Inc., Archon Capital Management LLC, Earnest Partners LLC, State Street Corp, and Point72 Asset Management L.P.. Company insiders that have bought OraSure Technologies stock in the last two years include Jack E Jerrett, Roberto Cuca, and Stephen S Phd Tang.
View insider buying and selling activity for OraSure Technologies

How do I buy shares of OraSure Technologies?

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OraSure Technologies' stock price today?

One share of OSUR stock can currently be purchased for approximately $11.89.

How big of a company is OraSure Technologies?

OraSure Technologies has a market capitalization of $852.91 million and generates $154.60 million in revenue each year. The medical instruments supplier earns $16.66 million in net income (profit) each year or $0.13 on an earnings per share basis. OraSure Technologies employs 472 workers across the globe.

What is OraSure Technologies' official website?

The official website for OraSure Technologies is www.orasure.com.

How can I contact OraSure Technologies?

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.